You are here

Oncogene DOI:10.1038/onc.2013.543

TRAF2 is an NF-κB-activating oncogene in epithelial cancers.

Publication TypeJournal Article
Year of Publication2013
AuthorsShen, RR, Zhou, AY, Kim, E, O'Connell, JT, Hagerstrand, D, Beroukhim, R, Hahn, WC
JournalOncogene
Date Published2013/12/23
ISSN0950-9232
Abstract

Aberrant nuclear factor (NF)-κB activation is frequently observed in human cancers. Genome characterization efforts have identified genetic alterations in multiple components of the NF-κB pathway, some of which have been shown to be essential for cancer initiation and tumor maintenance. Here, using patient tumors and cancer cell lines, we identify the NF-κB regulator, TRAF2 (tumor necrosis factor (TNF) receptor-associated factor 2), as an oncogene that is recurrently amplified and rearranged in 15% of human epithelial cancers. Suppression of TRAF2 in cancer cells harboring TRAF2 copy number gain inhibits proliferation, NF-κB activation, anchorage-independent growth and tumorigenesis. Cancer cells that are dependent on TRAF2 also require NF-κB for survival. The phosphorylation of TRAF2 at serine 11 is essential for the survival of cancer cells harboring TRAF2 amplification. Together, these observations identify TRAF2 as a frequently amplified oncogene.Oncogene advance online publication, 23 December 2013; doi:10.1038/onc.2013.543.

URLhttp://dx.doi.org/10.1038/onc.2013.543
DOI10.1038/onc.2013.543
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/24362534?dopt=Abstract